Anakinra for recalcitrant pyoderma gangrenosum

cb
Thumbnail Image
Files
ced.14809 (2).pdf(447.33 KB)
Published Version
Date
2021-06-16
Authors
O'Connor, Cathal
Gallagher, Catriona
Hollywood, Aoife
Paul, Lindsay
O'Connell, Michael
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc.
Published Version
10.1111/ced.14809
Research Projects
Organizational Units
Journal Issue
Abstract
Pyoderma gangrenosum (PG) is an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers. Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that blocks the activity of IL-1α and IL-1β by competitively inhibiting IL-1 binding to the IL-1 type I receptor. We present a series of two patients with recalcitrant PG, who had limited therapeutic options due to multiple previous treatment failures and multiple co-morbidities, who obtained 100% healing with anakinra. Compared to conventional first-line therapies for PG, the safety profile of anakinra may be preferable for patients with multiple co-morbidities. Further research is needed to assess the safety and efficacy of anakinra for PG.
Description
Keywords
Pyoderma gangrenosum , Anakinra
Citation
O'Connor, C., Gallagher, C., Hollywood, A., Paul, L. and O'Connell, M. (2021) 'Anakinra for recalcitrant pyoderma gangrenosum', Clinical and Experimental Dermatology. doi: 10.1111/ced.14809
Link to publisher’s version
URI
https://hdl.handle.net/10468/11763
Collections
Medicine - Journal Articles
INFANT Research Centre - Journal Articles
Copyright
© 2021, the Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of the British Association of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.